This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Earnings at Schering-Plough, AHP Reflect Ongoing Sagas

American Home Products (AHP - Get Report) and Schering-Plough (SGP) said earnings rose in the third quarter, although both were hampered by ongoing problems in their pharmaceutical operations.

American Home said earnings before costs associated with its ongoing Redux and Pondimin litigation were $867 million, or 65 cents a share, in the quarter, up from $762 million, or 58 cents a share, a year ago and two cents better than analysts' forecasts. The company said revenue rose 7% to $3.74 billion on a 9% increase in pharmaceutical sales.

The company also posted an after-tax charge of $615 million, or 46 cents a share, in the latest period for the diet-drug litigation, cutting its bottom-line profit to $252 million, or 19 cents a share. The expense represents expected future funding for a class-action settlement of the case, which has been in settlement proceedings for two years.

American Home said overall drug revenue was buoyed by brisk sales of Protonix, its gastroesophageal reflux treatment, and Effexor, an antidepressant. Those gains offset declines in products including its Premarin hormone-replacement therapy, sales of which fell because of promotions.

Meanwhile, Schering-Plough said it earned $601 million, or 41 cents a share, in the third quarter compared with $591 million, or 40 cents a share, a year ago. The results were in line with analysts' expectations. Revenue was roughly flat at $2.4 billion.

In the U.S., the company's overall drug sales fell 1% due to continuing manufacturing issues at two of its domestic plants. In a "disclosure notice" appended to its earnings release, Schering-Plough said future results could be affected by the FDA's investigation of those issues, which center on plants in New Jersey and Puerto Rico.

"We are continuing our broad efforts to resolve the manufacturing issues that are negatively affecting U.S. operations and results," the company said.

The Kenilworth, N.J., company said worldwide pharmaceutical sales rose 1% on higher sales in two segments: allergy and respiratory, and anti-infective and anticancer. Claritin sales were up 5% to $828 million while sales of Nasonex rose 39% to $136 million. Sales in its anticancer and antihepatitis line Intron A fell 11% to $301 million.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AHP $14.21 0.00%
AAPL $118.03 0.00%
FB $105.41 0.00%
GOOG $748.15 0.00%
TSLA $229.64 0.00%


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs